There are no results for this module. Edit the module to change the search term used to query related articles.
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
Investing in biotech companies can be viewed as "risky business" in today's world, with the FDA having a tight grip over the regulations needed for a product to reach the market. This year though, Discovery Laboratories Inc. (DSCO) introduced not one, bu Full Article at Seeking Alpha
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, reported that data from a preclinical study of SURFAXIN LS™ (lyophilized KL4 surfactant) was recently publi Full Article at News-Medical.net
Discovery Laboratories (DSCO) held a quarterly conference call on May 3 to update investors on the pending launch of Surfaxin and Afectair. This followed an important press release the day earlier that discussed a paper presented at the 2012 Pediatric Ac Full Article at Seeking Alpha
AtLeast one of the check box should be selected You are following news about Follow the latest news about DSCO WARRINGTON, Pa. , May 3, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advanc Full Article at PR Newswire
Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN®, when compared with infants treated wi Full Article at News-Medical.net
Keep track of the stocks that matter to you. Help yourself with the Fool's FREE and easy new watchlist service today. Protalix BioTherapeutics (AMEX: PLX ) is up more than 40% this year as investors poured into the company ahead of its return trip in fro Full Article at Motley Fool
Protalix BioTherapeutics (ASE: PLX) is up more than 40% this year as investors poured into the company ahead of its return trip in front of the Food and Drug Administration. The agency is scheduled to decide about its Gaucher disease treatment taliglucer Full Article at AOL News
Development-stage biotechnology company Discovery Laboratories Inc. said Thursday that its fourth-quarter loss narrowed on lower expenses and a stock-related gain. For the quarter ended Dec. 31, Discovery reported a net loss of $4.3 million, or 18 cents Full Article at CNBC
There are no results for this module. Edit this module to change the search term used to query related photos.
There are no results for this module. Edit this module to change the search term used to query Wikipedia
There are no results for this module. Edit the module to change the search term used to query related quotes.
We found no quotes related to Discovery Laboratories, Inc..
There are no results for this module. Edit the module to change the search term used to query Twitter.
We found no conversations related to Discovery Laboratories, Inc.
There are no results for this module.
A fresh, fun site featuring celeb gossip, fashion, beauty, love & sex, and health & fitness.
©Independent.ie Back to top